Trial Profile
An Open Label Multicenter Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Who Previously Received Treatment in Study LAL-CL01
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Sebelipase alfa (Primary)
- Indications Lysosomal storage diseases; Wolman disease
- Focus Adverse reactions
- Sponsors Alexion Pharmaceuticals; Synageva BioPharma
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 22 Jun 2018 Number of treatment arms have been changed from 3 to 1 by the removal of Experimental cohorts 1,2 and 3. Maximum age limit of 65 Years is removed. Primary end point has been changed.
- 22 Jun 2018 Status changed from active, no longer recruiting to completed.